"Novel developments in incretin-based medications for the treatment of type 2 diabetes and obesity"

Michael Nauck, MD
Head of Clinical Research
Diabetes Division of St. Josef-Hospital (Ruhr-University Bochum)
Bochum, North Rhine-Westphalia, Germany

Professor Michael Nauck, MD has a particular research interest in the role of gastrointestinal peptide hormones (incretins: glucose-dependent insulinotropic polypeptide, GIP, and glucagon-like peptide-1, GLP-1) in the physiological regulation of metabolism, in the pathophysiology of type 2 diabetes. He has contributed pivotal studies proving a therapeutic potential of GLP-1 in type 2 diabetes. In addition, Professor Nauck has also contributed his expertise to the development of incretin-based glucose-lowering medications such as GLP-1 receptor agonists and inhibitors of dipeptidyl peptidase-4.

This seminar is supported by EWCDI in partnership with the MDRC, MNORC, and MCDTR.